Does THC-P Show Up in a Drug Test?

THC-P will almost certainly trigger a positive result on a standard drug test. The compound is structurally so close to conventional THC that it cross-reacts with the antibodies used in urine immunoassay screens, and its metabolic breakdown products closely mirror those of regular THC. Because drug tests are designed to catch THC and its metabolites rather than just one specific version of THC, newer cannabinoid analogs like THC-P fall squarely in the detection net.

What THC-P Is and Why It Matters for Testing

THC-P, formally called delta-9-tetrahydrocannabiphorol, is a naturally occurring cannabinoid first isolated and characterized by Italian researchers in 2019. Its molecular structure is nearly identical to regular delta-9-THC, with one key difference: it has a seven-carbon alkyl side chain instead of THC’s five-carbon chain. That longer chain makes it bind far more tightly to the CB1 receptor in the brain. In receptor binding studies, THC-P showed roughly 33 times the affinity for the human CB1 receptor compared to delta-9-THC.¹

That potency matters for drug testing in a practical way. Because THC-P is so potent, users typically consume smaller absolute amounts to achieve effects. But the structural similarity to THC means your body handles it in ways that look very familiar to a drug test’s detection system. The compound doesn’t sneak under the radar just because it has a slightly longer carbon chain.

Why THC-P Triggers the Initial Screening

Most drug tests begin with an immunoassay, a rapid screening method that uses antibodies designed to latch onto THC-related molecules. These antibodies are not perfectly specific to delta-9-THC alone. They recognize a general molecular shape shared by THC and many of its structural relatives. When THC-P was included in spiking experiments alongside several other cannabinoid analogs, it cross-reacted with the antibodies used in the immunoassay screen.²

Cross-reactivity is a feature of immunoassays, not a flaw. These tests are built to cast a wide net. They are meant to flag anything that looks like a THC-family compound so it can be examined more closely. The practical result is that if you have recently used THC-P and provide a urine sample, the screening step is very likely to come back positive for THC, even though you haven’t consumed conventional cannabis.

How Your Body Breaks Down THC-P

Once THC-P enters your system, your liver processes it through the same enzymatic pathways that handle regular THC. Research using human liver microsomes showed that THC-P and other THC analogs with varying side chain lengths all produced hydroxylated and carboxylated metabolites similar to those of delta-9-THC.³

This is the crux of why THC-P is so difficult to dodge on a test. Drug tests for cannabis don’t actually look for THC itself in most cases. Urine tests look for THC-COOH, the carboxylated metabolite your liver creates after processing THC. Because THC-P goes through the same metabolic steps and generates a structurally analogous carboxylated product, your body is essentially producing the evidence a drug test is trained to find. Even if a test were somehow blind to the parent THC-P molecule, the metabolites it leaves behind still look like cannabis metabolites.

What Happens at the Confirmatory Stage

If an immunoassay comes back positive, the sample typically goes to a second, more precise test. In workplace and forensic settings, this is usually a chromatographic method such as liquid chromatography coupled with tandem mass spectrometry. These instruments separate individual molecules by weight and chemical properties, and they can tell the difference between delta-9-THC, delta-8-THC, THC-P, and many other analogs.

A comprehensive analytical method published in 2025 demonstrated the ability to qualitatively confirm THC-P itself, along with its metabolites, in both blood and urine. The method could detect non-carboxylated analytes at concentrations as low as 1 ng/mL and carboxylated metabolites down to 5 ng/mL.⁴

Here is where it gets nuanced. Not every lab runs a panel broad enough to specifically identify THC-P. Many confirmatory methods are calibrated to look for delta-9-THC-COOH, the metabolite of conventional THC. Because THC-P’s metabolites are similar but not identical, a lab running a narrower confirmation panel might report the result as positive for “THC metabolites” in a general sense. Some labs may not distinguish THC-P metabolites from regular THC metabolites at all. In practice, though, this distinction rarely helps the person being tested. A positive confirmation for THC metabolites is a positive confirmation, regardless of which THC family member produced them.

How Workplace Testing Cutoffs Work

Federal workplace drug tests in the United States follow guidelines set by the Department of Health and Human Services. The standard process uses a 50 ng/mL cutoff for the initial immunoassay screen and a 15 ng/mL cutoff for the confirmatory test. Studies have shown about 93% agreement between the immunoassay and confirmatory stages when these cutoffs are applied.⁵

These cutoffs were designed with delta-9-THC in mind, and the federal guidelines don’t specifically name THC-P. But the cutoffs are based on metabolite concentrations, and THC-P’s metabolites register on these assays just as delta-8-THC metabolites do. Research on delta-8-THC, another analog that has recently surged in popularity, found that its carboxylated metabolite appeared at similar concentrations as conventional THC-COOH in workplace specimens, supporting the use of the same cutoffs and decision rules for both.⁶ The same logic extends to THC-P. If your body is producing carboxylated metabolites above the cutoff threshold, the test reports positive.

How Long THC-P Stays Detectable

There is no published human pharmacokinetic study tracking exactly how long THC-P remains detectable in urine, blood, or saliva. That gap exists because THC-P only entered the consumer market within the last few years, and the kind of controlled dosing studies needed to map its elimination timeline haven’t been completed yet.

What we can say is that THC-P is highly lipophilic, meaning it dissolves readily in fat. This is a property it shares with delta-9-THC, which is famously slow to clear from the body because it stores in fatty tissue and releases gradually. THC-P’s longer carbon chain likely makes it even more fat-soluble than regular THC, which could mean a longer detection window. But that is an inference based on chemistry, not a measured result.

For conventional THC, single or infrequent use can produce a positive urine result for roughly three to five days, while heavy daily users sometimes test positive for a month or more. Given what we know about THC-P’s metabolism and fat solubility, expecting at least comparable detection windows is reasonable. If anything, heavy or repeated use of THC-P could push that window longer, but no one has measured it precisely.

Different Test Types and THC-P

The discussion so far has focused on urine testing because that is the most common format for workplace and legal testing. But other sample types behave somewhat differently.

Blood tests: The same comprehensive analytical method that detects THC-P in urine also works in blood, with detection limits as low as 1 ng/mL for the parent compound.⁴ Blood tests typically reflect more recent use and have a shorter detection window than urine.
Oral fluid tests: Saliva testing is growing more common, especially in roadside impairment checks. These tests also use immunoassay-based screening, and the same cross-reactivity that catches THC-P in urine tests applies here. No published data specific to THC-P in oral fluid exists yet, but the antibody-based detection mechanism is the same.
Hair tests: Hair testing captures drug use over a much longer period, typically about 90 days. No peer-reviewed studies have specifically looked at THC-P incorporation into hair, so the detection window for this particular analog remains unknown. Hair tests for conventional THC are already considered less reliable for light or infrequent users, and the same uncertainty would apply to THC-P.

Can You Argue It Wasn’t “Real” THC?

Some people assume that because THC-P is technically a different molecule from delta-9-THC, a positive drug test result could be challenged on those grounds. In most situations, this argument doesn’t hold up.

Workplace drug testing under federal guidelines tests for “marijuana metabolites,” which is a category, not a single molecule. The confirmatory assay identifies THC-COOH-class metabolites, and if your sample contains them above the cutoff, the result stands. A medical review officer evaluating the test isn’t asked to determine which specific version of THC produced the metabolite. They are asked whether the sample is positive or negative for marijuana metabolites.

Even in situations where a more detailed analytical method does identify THC-P specifically, that doesn’t necessarily help. THC-P is a controlled substance analog in many jurisdictions. In the United States, the Federal Analogue Act treats any substance substantially similar to a Schedule I drug as a Schedule I substance when intended for human consumption. Several countries have moved faster: Sweden classified THC-P as a narcotic in 2023, and it promptly disappeared from shops there, replaced by other unregulated variants.²

The one scenario where distinguishing THC-P from THC might matter is a legal defense where the source of the cannabinoid is relevant, for example, if someone consumed a product marketed as legal hemp and wants to show the positive test came from an unexpected contaminant. Even then, the positive test result itself isn’t nullified; the question shifts to who is responsible for the exposure.

The Unregulated Product Problem

THC-P products are sold in a regulatory gray area in many places. They are often marketed alongside delta-8-THC, HHC, and other hemp-derived cannabinoids as “legal alternatives” to marijuana. The problem is that these products are largely unregulated, and what’s on the label may not reflect what’s in the bottle.

A product labeled as containing THC-P could also contain delta-9-THC, delta-8-THC, or other cannabinoids that independently trigger drug tests. Contamination or mislabeling is common in this market. Even if you were trying to consume only a trace amount of THC-P, the actual product might deliver a much larger dose of conventional THC metabolites than you expected. This makes the drug test risk even harder to predict or control.

From a testing standpoint, it doesn’t matter whether the THC-COOH in your urine came from THC-P you chose to consume or from delta-9-THC that was an undisclosed contaminant. The result is the same.

The Broader Landscape of Novel Cannabinoids and Drug Testing

THC-P is just one entry in a rapidly expanding catalog of cannabinoid analogs reaching consumers. Delta-8-THC, HHC, HHC-P, THC-H, THC-B, and THC-O have all appeared in consumer products over the past few years. The drug testing field has been working to keep up, and the picture that’s emerging is consistent: the closer a compound is to delta-9-THC in structure, the more likely it is to cross-react on immunoassay screens and to produce metabolites that confirmatory methods can detect.

Research on delta-8-THC in workplace testing found that its carboxylated metabolite showed up at median concentrations similar to those of conventional THC-COOH, confirming that the same screening and confirmation cutoffs catch both.⁷ The same principle extends to THC-P and other homologs. Labs are also actively developing broader panels. The comprehensive method that can detect THC-P also covers THCB, THCH, THCV, and hexahydrocannabiphorol in a single run.⁴

This is the direction forensic and workplace toxicology is heading. Rather than testing for a single target molecule, labs are building methods that catch the entire family of THC-related compounds and their metabolites at once. The metabolic research confirming that THC analogs with different chain lengths all produce the same types of phase I metabolites gives labs a reliable set of analytical targets to look for.³

What People Get Wrong About “Legal” Cannabinoids and Testing

The most common misconception is that “legal” means “undetectable.” These two things have nothing to do with each other. A cannabinoid can be sold legally in your state because regulators haven’t gotten around to banning it, while simultaneously being trivially easy for a drug test to detect. The legal status of the product you bought has no bearing on what the test measures.

A second misconception is that you can flush THC-P from your system quickly by drinking large volumes of water or using detox products. Dilution can sometimes bring urine metabolite concentrations below the cutoff temporarily, but labs check for abnormally dilute samples and may flag them as invalid. An invalid result typically means you have to test again, sometimes under observed conditions. Detox supplements marketed for this purpose have no scientific evidence supporting their effectiveness.

A third misconception is that because THC-P is more potent, you use less of it, so there’s less metabolite to detect. While it’s true that a person might consume a smaller dose, drug test cutoffs are set low enough that even modest amounts of THC-class metabolites produce positive results. The 15 ng/mL confirmatory cutoff for workplace testing is extremely sensitive. You don’t need to consume much of any THC-related compound to exceed it.

If you are subject to drug testing of any kind and are considering using THC-P, the evidence consistently points in one direction: it will behave like THC on every type of drug test currently in use, from the initial screen through confirmatory analysis. No version of THC with a slightly different side chain has been shown to evade detection, and as labs expand their analytical panels, the ability to identify these compounds specifically is only improving.

1
PubMed Central. A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol – Section: Binding affinity at human CB1 and CB2 receptors
2
PubMed. Appearance of hexahydrocannabinols as recreational drugs and implications for cannabis drug testing – focus on HHC, HHC-P, HHC-O and HHC-H
3
Oxford Academic (Journal of Analytical Toxicology). Delta-9-tetrahydrocannabutol, delta-9-tetrahydrocannabihexol, and delta-9-tetrahydrocannabiphorol: the impact of varying alkyl chain length on delta-9-tetrahydrocannabinol analog metabolism
4
Oxford Academic (Journal of Analytical Toxicology). Comprehensive LC–MS-MS analysis of THC isomers, analogs, homologs, and metabolites in blood and urine
5
Journal of Analytical Toxicology. Prevalence of Cannabidiol, ∆9- and ∆8-Tetrahydrocannabinol and Metabolites in Workplace Drug Testing Urine Specimens – Section: Immunoassay
6
PubMed. Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing
7
Journal of Analytical Toxicology. Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing